U.S. markets close in 4 hours 26 minutes
  • S&P 500

    4,204.90
    +82.43 (+2.00%)
     
  • Dow 30

    33,317.11
    +542.70 (+1.66%)
     
  • Nasdaq

    12,819.30
    +325.38 (+2.60%)
     
  • Russell 2000

    1,960.09
    +47.20 (+2.47%)
     
  • Crude Oil

    89.91
    -0.59 (-0.65%)
     
  • Gold

    1,816.10
    +3.80 (+0.21%)
     
  • Silver

    20.77
    +0.29 (+1.41%)
     
  • EUR/USD

    1.0348
    +0.0130 (+1.27%)
     
  • 10-Yr Bond

    2.7480
    -0.0490 (-1.75%)
     
  • GBP/USD

    1.2252
    +0.0176 (+1.46%)
     
  • USD/JPY

    132.4760
    -2.6400 (-1.95%)
     
  • BTC-USD

    24,017.75
    +884.63 (+3.82%)
     
  • CMC Crypto 200

    565.11
    +33.89 (+6.38%)
     
  • FTSE 100

    7,503.10
    +14.95 (+0.20%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Acadia Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 8, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Company to host conference call and webcast on Monday, August 8, 2022, at 4:30 p.m. Eastern Time

SAN DIEGO, July 25, 2022--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 8, 2022, at 4:30 p.m. Eastern Time to discuss financial results and operations.

The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call. The registration link will also be available on Acadia’s website, www.acadia.com under the investors section and will be archived there until September 5, 2022.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements include but are not limited to statements regarding the timing of future events. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval and commercialization. For a discussion of these and other factors, please refer to Acadia’s annual report on Form 10-K for the year ended December 31, 2021 as well as Acadia’s subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Acadia undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005795/en/

Contacts

Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com

Investor Contact:
Acadia Pharmaceuticals Inc.
Mark Johnson, CFA
(858) 261-2771
ir@acadia-pharm.com